Maria Soloveychik's guest appearances

Maria Soloveychik

IndieBio -Designing Science

Biotech 2050 Podcast

Peter Diamandis

David Eagleman

Rick Doblin

Robert Gould

Jim Collins

Jim Burns

Jamie Wheal

David Berry

David Bates

Dariush Mozaffarian

Jim Sullivan

Melanie Matheu

Arvind Gupta

Tim Sweeney

Tim Miller

OwlTail

Dr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technologies, ToRPPIDO and ToRNeDO, rely on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt protein-protein interactions or lead to selective target degradation. SyntheX was founded in 2016 and is located in San Francisco.Maria has obtained her PhD from the Department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a research scientist at a structural genomics consortium at the University Health Network in Toronto, where her work led to the determination of numerous structures and identification of several drug candidates.

Dr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technologies, ToRPPIDO and ToRNeDO, rely on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt protein-protein interactions or lead to selective target degradation. SyntheX was founded in 2016 and is located in San Francisco. Maria has obtained her PhD from the Department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a research scientist at a structural genomics consortium at the University Health Network in Toronto, where her work led to the determination of numerous structures and identification of several drug candidates.

30. Genetics and synthetic biology for trailblazing drug discovery, Maria Soloveychik, CEO, SyntheX

Maria Soloveychik, co-founder and CEO of SyntheX featured on "Designing Science" podcast with Arvind Gupta, Founder and Managing director of IndieBio.IndieBio is a leading seed-stage life science accelerator program devoted to funding and building startups dedicated to solving humanity’s most pressing problems through biology.We enable the best scientists to become entrepreneurs, and nurture the future leaders of movements and systemic change. Our technology focus is on reinventing the food and water supply chain, medicine, healthcare, diagnostics, agriculture, and biomaterial industries. To date, 116 companies have graduated from the program, with a combined current valuation of over $2B.IndieBio is a member of SOSV a $700M global fund focused on lasting impact.Follow on www.twitter.com/indbio

Maria Soloveychik, co-founder and CEO of SyntheX featured on "Designing Science" podcast with Arvind Gupta, Founder and Managing director of IndieBio. IndieBio is a leading seed-stage life science accelerator program devoted to funding and building startups dedicated to solving humanity’s most pressing problems through biology. We enable the best scientists to become entrepreneurs, and nurture the future leaders of movements and systemic change. Our technology focus is on reinventing the food and water supply chain, medicine, healthcare, diagnostics, agriculture, and biomaterial industries. To date, 116 companies have graduated from the program, with a combined current valuation of over $2B. IndieBio is a member of SOSV a $700M global fund focused on lasting impact. Follow on <a href="http://www.twitter.com/indbio" rel="nofollow" target="_blank">www.twitter.com/indbio</a>

Arvind Gupta and Maria Soloveychik